AzTrials
AzTrials

Spinal AnesthesiaNCT05751148

Cardiovascular Effects of Intrathecal Hyperbaric Prilocaine or Bupivacaine in Surgery Under Spinal Anesthesia

A study testing Hyperbaric bupivacaïne and Hyperbaric prilocaïne in people with Spinal Anesthesia and Cardiac Toxicity, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Spinal anesthesia remains a mainstay in lower limbs- as in day-case surgeries as well. It consists in injecting a local anesthetic drug into the intrathecal space of a patient's spinal canal. Read more about this study

Who is it for?
Ages 18 to 65 years, men only
Conditions the study is for
Spinal Anesthesia, Cardiac Toxicity
What is being tested?
Hyperbaric bupivacaïne and Hyperbaric prilocaïne
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteBelgium
Study dates
22 Mar 2023to 30 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male
  • 165 cm < x < 180 cm
  • Aged of 18 or more and less than 65
  • Elective surgery under spinal anesthesia
  • American Society of Anesthesiology (ASA) I or II

Who cannot join

  • History of heart disease: ischemic or valvular
  • Atrial fibrillation
  • Cardiotropic medication
  • Cardiovascular disease history
  • Norepinephrine uptake medication
  • Urgent surgery
Show all 11Show fewer
  • History of narrow spinal canal
  • Hemostasis abnormalities or local skin infection
  • Hypersensitivity to local anesthetics
  • Failure of spinal anesthesia leading to plan change during surgery
  • Patient's refusal

Trial locations and contacts

1 site in 1 country.

Belgium1 site, 1 recruiting
  • Saint Pierre University Hospital

    Brussels, 1000

    Daniel Patricio, MD., 02 535 42 86 ext. +32, daniel.patricio@stpierre-bru.be

    Panayota Kapessidou, MD. PhD, 02 535 37 50 ext. + 32, panayota.kapessidou@stpierre-bru.be

    Recruiting

Other trials in Belgium

About this study

Official title: Cardiovascular Effects of Intrathecal Hyperbaric Prilocaine or Bupivacaine in Surgery Under Spinal Anesthesia: A Multicenter Prospective Pilot Study Based on Non- Invasive Haemodynamic Monitoring

Spinal anesthesia remains a mainstay in lower limbs- as in day-case surgeries as well. It consists in injecting a local anesthetic drug into the intrathecal space of a patient's spinal canal. To achieve a suitable sensory and motor block for elective or emergent surgery, the anesthetist must adapt his choice of local anesthetic to the surgery's requirements and the patient's comorbidities, too.

Spinal anesthesia is often associated with adverse cardiovascular events, notably hypotension which is a major concern in current anesthetic practice, especially in specific patient populations.

Read more

Spinal induced hypotension is reported to be commonly related to the sympathetic block level and may be linked to perioperative cardiac and renal complications. Several mechanisms might play a role in the incidence of perioperative hypotension after spinal puncture. A decrease in peripheric systemic vascular resistance from arterial vasodilatation, a reduction of cardiac output due to a decrease in preload from a redistribution of venous blood into lower limbs or even an occurrence or increment of cardiac dysfunction, might compound proper blood flow towards noble organs such as brain, heart and kidneys. Spinal induced hypotension may also be related to a direct reduction of cardiac contractibility by the local anesthetic injection.

Compensating mechanisms might be inhibited depending on the level of sympathetic blockade, usually related to the dose of the local anesthetic. Former studies found that intrinsic left ventricular depression might occur during spinal anesthesia as left ventricular volumes per se remain stable. One noticed that diastolic and systolic function (i.e., ventricular outflow tract velocity) decreased significantly after intrathecal levobupivacaine plus fentanyl injection based on transthoracic ultrasound assessment. Other authors use Pro-Brain Natriuretic Peptide to assess myocardial stress induced by surgery and anesthetic management. Other serum markers such as Cortisol, Adreno Cortico-Trope Hormone, Angiotensin are identified to screen and monitor myocardial stress as for instance acute myocardial dysfunction.

Hyperbaric prilocaine is an intermediate-acting local anesthetic, whereas bupivacaine may be intermediate- or long-acting depending on the employed dose. Both drugs provide comparable sensory and motor block that meet the anesthesia level requirements in various surgical procedures.

In regard to the hemodynamic effects, hypotension has been largely reported following hyperbaric bupivacaine in a dose-dependent way. However, discrepancy exists between the rare studies having investigated prilocaine's effects, probably related to the methodology and the employed doses. Moreover, the hemodynamics effects of these local anesthetics have been barely specifically investigated in a non-cesarean section context.

The aim of this study is to compare the cardiovascular effects inflicted by hyperbaric prilocaine and bupivacaine under spinal anesthesia. Cardiovascular response will be assessed by non-invasive hemodynamic monitoring whereas metabolic stress will be evaluated using serum stress markers.

Read the detailed description

The investigators will conduct a double blinded pilot study in adult patients scheduled for elective surgery under spinal anesthesia. Selected interventions with few hemodynamic variations and minimal liquid shifts are knee arthroscopy, orthopedic lower limb surgery using a tourniquet, uni- or bilateral saphenectomy, ureteric stent insertion, inguinal hernia repair, vasectomy and penile circumcision.

  1. Population Patients will be included in the study, after reading, understanding, and signing the consent documents explaining the goals and the procedure of the study protocol. The study will take place in the departments of Anesthesiology and Pain Medicine of the Saint-Pierre University Hospital and Edith Cavell Interregional Hospital Group - Site Braine l'Alleud, in collaboration with their respective departments of surgery. Considering that the present study is a pilot study, the number of patients to be included has been determined to be 30 in each study group for a total of 60 patients. The trial will end when the whole enrolled population will be subjected to the current protocol on elective surgery under spinal anesthesia. The primary goal is to assess patients' cardiac output variation between the pre-spinal period and 20 minutes after intrathecal anesthesia. Following ethics committee approval and informed signed consent, enrolled patients will be assigned after randomization into 2 groups Group 1 : Spinal anesthesia using 10 mg of hyperbaric bupivacaine 0,5% Group 2 : Spinal anesthesia using 50 mg of hyperbaric prilocaine 2% In both groups, spinal anesthesia will be performed by an attending anesthetist different than the one doing the ultrasound assessment to assure double blindness of this study. To preserve double blindness, 0,5 ml of NaCl 0,9% is added to the bupivacaine solution.
  2. Anesthetic management
  3. Pre-procedural
  4. Pre-operative patient consultation Aim: evaluate overall perioperative risks and to assess patient's eligibility for the current study. Usual biological screening comprising blood count, coagulation tests and kidney function will be prescribed at the attending's discretion. Patient will be given information about the study protocol and, if eligible, an informed consent will be signed.
  5. Anxiolysis

To reduce the impact of psychological stress on the day of surgery, patients are premedicated with 0,5 mg alprazolam.

ii. Intra-procedural

  1. Setup After admission in the day-care department, the patient is correctly installed, undressed and prepared for surgery. Before carried to the operating theater, a blood sample is obtained to measure basal values of serum markers reflecting cardiac stress i.e.:
  • Cortisol
  • ACTH
  • Pro-BNP
  • Angiotensin
  • IL-1 - IL - 6
  • IL-10 After the blood sample is obtained, vital parameters are collected such as heart rate, arterial pressure and oxygen saturation.
  1. Pre-loading A peripheral intravenous line is threaded, and a crystalloid solution perfused at a flow rate determined by the Holliday - Segar 4-2-1 - rule using a Dial-A-Flow device (Wolf Medical Supply, Sunrise, Florida, United States). Pre-operative hypovolemia may increase spinal anesthesia induced hypotension. Inferior vena cava collapsibility during respiratory cycles, measured with an ultrasound device, has shown interest in prediction fluid responsiveness in critical ill patients with septic shock. Preau et al. showed a positive correlation between higher valued of IVCc and fluid responsiveness in patients with spontaneous breathing. Patients whom IVCc exceeds 40% during basal measuring prior to spinal puncture, are pre-loaded with a fluid challenge of 100 ml of a colloid solution for 5 minutes. This procedure is repeated till obtaining a normovolemic state. Another measurement of the patient's IVCc is done after the 5-minute fluid challenge. If the value of IVCc is less than 48%, the investigators then proceed to transthoracic echocardiographic assessment.
  2. First cardiac ultrasound assessment Before spinal anesthesia, an extended cardiac ultrasound assessment is realized by the same operator for the entire study duration. Following values are either measured or derived from previous ones:
  • Left ventricular ejection fraction (LVEF)
  • Left ventricular outflow tract velocity integral (VTI)
  • Stroke volume (SV)
  • Cardiac output (CO)
  • Fractional shortening of the left ventricle (FR)
  • Systemic vascular resistance (SVR) (calculated) (PAM - PVC / CO x 80)
  • Diastolic inflow: E and A peak velocities
  • E/A ratio \& E/E'
  • Tissue Doppler imaging (TDI) for septal and lateral mitral annulus motion (E')
  • TDI for systolic velocity of the tricuspid annulus (S')
  • Tricuspid annular plane systolic excursion (TAPSE)
  • Peak tricuspid regurgitation velocity
  • Pulmonary artery systolic pressure (PAPs) All the Doppler variables are determined by averaging the values measured over three consecutive cardiac cycles.
  1. Novel non-invasive hemodynamic assessment using Clear Sight Hemodynamic variables such as VVE, SV, SVR and Cardiac Output can be easily obtained with the new Clear Sight device from Edwards Electronics. The latter has been approved and validated for its reliability according to other more invasive cardiac output measuring devices. Moreover, the Clear Sight is used as a guarantor of plausible hemodynamic values obtained by transthoracic ultrasound in this setting. The Clear Sight device has the advantage of being fully handy and ready to use after a fast initial calibration with its Heart-rate-sensor.
  2. Spinal anesthesia Spinal anesthesia (SA) is always performed in a sitting position by a different staff anesthetist than the one doing cardiac assessment. To do so, manual palpation and ultrasound spotting identifies L3-L4 intervertebral space. Using a 25-Gauge Withacre needle (BD, Franklin Lakes, NJ, USA) in a midline approach, either 50 mg of hyperbaric prilocaine (2,5 mL) or 10 mg of hyperbaric bupivacaine + 0,5 mL NaCL 0,9% (2,5 mL) are injected into intrathecal space after positive barbotage test. After the procedure, the patient remains immediately in a supine position. HR and NIBP are continually measured at 5-minute intervals until the end of surgery. The dermatome level of the sensory block is obtained with the cold- and the pin-prick test bilaterally. Attainment of an at least Th7 level signifies a good quality block for urological-, gynecological-, lower abdominal- and lower limb surgery, respectively.
  3. Second cardiac ultrasound assessment, clear sight assessment and cardiac biomarkers The second cardiac evaluation will be done twenty minutes after intrathecal injection. If the sensory block is found to be insufficient (i.e. below Th7) twenty minutes after spinal puncture, another five minutes are awaited to undergo second echocardiographic assessment. All the mentioned values from the first cardiac assessment are collected. Another blood sample is obtained for cardiac stress markers determination.
  4. Surgery

Surgery rarely exceeds one hour. If used, tourniquet is inflated to 350 mmHg. Minimal blood loss is expected during all selected interventions. This procedural environment allows to practically characterize our subjects as "healthy" subjects undergoing spinal anesthesia.

  • Spinal anesthesia failure

In case of insufficient sensory block, the anesthetic plan is converted into general anesthesia and the patient is excluded from per procedural analyses.

  • Hypotension Protocol

Hypotension is defined as a Mean BP (MBP) < 65 mmHg. It is treated using intravenous ephedrine: 6-mg boluses every five minutes if necessary.

  • Bradycardia Protocol

Bradycardia is defined as a decrease of 20% of basal heart rate. Symptomatic bradycardia is treated with intravenous atropine: 0,5 mg repeated, if necessary, based on physician's discretion.

iii. Postoperative

  1. Postoperative analgesia Postoperative analgesia is administrated as soon as the patient returns to ward. A multimodal approach using paracetamol and non-steroidal anti-inflammatory drugs is applied. First NSAID dose is given per os preoperatively. Post-operative analgesic medication consists of paracetamol, NSAID and second stage analgesics such as tramadol if necessary. Third stage analgesics such as morphine and piritramide are barely used but administered if necessary, at the anesthetist's discretion.
  2. Third cardiac ultrasound assessment, clear sight assessment and cardiac biomarkers

After complete offset of sensory and motor block, patients undergo a last transthoracic ultrasound examination. Variables are compared to those gathered from the Clear Sight non-invasive hemodynamic device. A further blood sample is obtained, and the patient is discharged from PACU.

Being tested
Hyperbaric bupivacaïne, Hyperbaric prilocaïne
Keywords
Hyperbaric Bupivacaine, Hyperbaric Prilocaine, Non-Invasive Hemodynamic Assessment, Clear Sight Edwards, Cardiac Ultrasound, Cardiac Output, Stroke Volume Variation
Medical subject headings
Cardiotoxicity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Hyperbaric bupivacaïneDrug

    Also called Hyperbaric Marcaïne

    Spinal anesthesia with 10mg of hyperbaric bupivacaïne. A syringe filled with 2 mL of hyperbaric bupivacaïne + 0,5 ml of saline solution

  • Hyperbaric prilocaïneDrug

    Also called Tachipri

    Spinal anesthesia with 50mg of hyperbaric prilocaïne. A syringe filled with 2,5 mL of hyperbaric prilocaïne

Study groups in NCT05751148
Study groupRoleWhat they receive
Group 1: Hyperbaric BupivacaineActive comparatorNot described
Receives: Drug: Hyperbaric bupivacaïne
Group 2: Hyperbaric PrilocaineActive comparatorNot described
Receives: Drug: Hyperbaric prilocaïne

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in cardiac output assessed by Clear Sight device

    Cardiac output (liters per minute) will be assessed by the Clear Sight non-invasive hemodynamic system before spinal anesthesia (baseline), 20 minutes after spinal anesthesia and before discharge from the post anesthesia care unit (PACU).

    Measured: Up to two hours post surgery

  2. Change in cardiac output assessed by transthoracic Ultrasound

    Cardiac output (liters per minute) will be assessed by ultrasound assessment before spinal anesthesia (baseline), 20 minutes after spinal anesthesia and before discharge from the post anesthesia care unit (PACU).

    Measured: Up to two hours post surgery

  3. Stroke Volume Variation assessed by the Clear Sight device

    Stroke volume variation (%) will be assessed by the Clear Sight non-invasive hemodynamic system before spinal anesthesia, 20 minutes after spinal anesthesia and before discharge from the post anesthesia care unit (PACU).

    Measured: Up to two hours post surgery

  4. Stroke Volume Variation assessed by transthoracic Ultrasound

    Stroke volume variation (%)will be assessed by ultrasound assessment before spinal anesthesia, 20 minutes after spinal anesthesia and before discharge from the post anesthesia care unit (PACU).

    Measured: Up to two hours post surgery

Secondary outcomes (11)
  1. Highest dermatome level

    Highest dermatome level is assessed by the loss of sensitivity to cold at 20 minutes after spinal anesthesia.

    Measured: 20 minutes after spinal anesthesia

  2. Motor block

    Maximal intensity is assessed by the use of Bromage score at 20 minutes after spinal anesthesia.

    Bromage Score is a validated score which assesses patient's capacity to move lower limbs. It goes from 0 = free movement of legs and feet to 3 = unable to move legs or feet.

    Measured: 20 minutes after spinal anesthesia

  3. Adrenocorticotropic Hormone (ACTH)

    Adrenocorticotropic Hormone (ACTH) in pg/mL will be measured in blood samples before spinal anesthesia, 20 minutes after spinal anesthesia and just before discharging from PACU.

    Measured: Up to two hours post surgery

  4. Cortisol

    Cortisol in microgram/dL will be measured in blood samples before spinal anesthesia, 20 minutes after spinal anesthesia and just before discharging from PACU.

    Measured: Up to two hours post surgery

  5. Dosage of Neuro-Inflammatory Markers

    Interleukine-1, Interleukine-6, and Interleukine-10 will be measured in blood samples before before spinal anesthesia, 20 minutes after spinal anesthesia and just before discharging from PACU.

    Measured: Up to two hours post surgery

  6. Angiotensine

    Angiotensine in microgram/L will be measured in blood samples before before spinal anesthesia, 20 minutes after spinal anesthesia and just before discharging from PACU.

    Measured: Up to two hours post surgery

  7. Pro-BNP

    Pro-BNP ng/L will be measured in blood samples before before spinal anesthesia, 20 minutes after spinal anesthesia and just before discharging from PACU.

    Measured: Up to two hours post surgery

  8. Total Vasopressor Dose

    Total Vasopressor Dose used throughout the intervention to maintain Arterial Pressure within a pre-defined individualized ranges ( >= 65 mmHg).

    Measured: Up to two hours post surgery

  9. Bradycardia episodes

    Bradycardia episodes are counted as single events when patient's heart rate drops below 20% of basal heart rate in beats per minute.

    These episodes are treated at the physicians discrepancy with 0,5 mg of atropine.

    Measured: Up to two hours post surgery

  10. Surgeon's Satisfaction

    Surgeon's satisfaction will be assessed using an arbitrary scale:

    1 - Satisfied, 2 - Some discomfort, 3 - Fully unsatisfied

    Measured: Through surgery completion, an average of one hour after spinal anesthesia

  11. Patient's satisfaction

    Patient's satisfaction will be assessed using an arbitrary scale:

    1 - Satisfied, 2 - Some discomfort, 3 - Fully unsatisfied

    Measured: Up to two hours post surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2023
  2. Study start22 Mar 2023
  3. Primary completion30 Sep 2023 (estimated)
  4. Study completion30 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05751148
Sponsor's protocol ID
B0762023230106
Status last verified
Mar 2023
First submitted
22 Jan 2023
Last updated
24 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Hyperbaric bupivacaïne and Hyperbaric prilocaïne in people with Spinal Anesthesia and Cardiac Toxicity, run by Centre Hospitalier Universitaire Saint Pierre at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Daniel Patricio, MD. (025354286 ext. +32, daniel.patricio@stpierre-bru.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in cardiac output assessed by Clear Sight device (time frame: Up to two hours post surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT05751148 | AzTrials